¼³¸í ¾È µÇ´Â Áõ»ó(MMUS)¿¡ ´ëÇÑ ÀÇÇÐÀû Á¢±Ù
2006³â Ãá°èÇмú´ëȸ
Á¤½ÂÇÊ, ¿µ³²ÀÇ´ë °¡Á¤ÀÇÇаú |
|
NSAID ¾î¶»°Ô ó¹æÇÒ °ÍÀΰ¡?
2006³â Ãá°èÇмú´ëȸ
ÀÌâ±Ù, ¼¿ï¾Æ»êº´¿ø ·ù¸¶Æ¼½º ³»°ú |
|
º¸Å彺¿Í ÇÊ·¯ ½Ã¼úÀÇ ±âº»
2006³â Ãá°èÇмú´ëȸ
¾ÈÁöÇö, µå¸²Å¬¸®´Ð |
|
¹ß±âºÎÀüÀÇ »õ·Î¿î ¾à¹°
2006³â Ãá°èÇмú´ëȸ
¾ÈÅ¿µ, ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø ºñ´¢±â°ú |
|
¼Ò¾Æºñ¸¸ÀÇ Ä¡·á - °¡Á·À» ¾î¶»°Ô ÁßÀçÇÒ °ÍÀΰ¡ -
2006³â Ãá°èÇмú´ëȸ
±è¹Ì¸®Çý, ´ö¼º¿©ÀÚ´ëÇб³ |
|
¼Ò¾Æ ºñ¸¸ÀÇ Áø´Ü°ú Æò°¡, Ä¡·á Á¢±Ù
2006³â Ãá°èÇмú´ëȸ
À¯¼±¹Ì, ÀÎÁ¦ÀÇ´ë »ó°è¹éº´¿ø °¡Á¤ÀÇÇаú |
|
°íÇ÷¾Ð ARB ¾à¹° ó¹æÀÇ ±¹³» °æÇè
2006³â Ãá°èÇмú´ëȸ
±è¿µ½Ä, ¿ï»êÀÇ´ë ¼¿ï¾Æ»êº´¿ø °¡Á¤ÀÇÇаú |
|
ÀÏÂ÷Áø·á¿¡¼ ·¹ÀÌÀú Ä¡·áÀÇ ABC
2006³â Ãá°èÇмú´ëȸ
±è¹ÎÁ¤, ¹ÌÇϳª Ŭ¸®´Ð |
|
Current Trend of LDL Lowering Management
2005³â Ãß°èÇмú´ëȸ
ÇѱâÈÆ, ¿ï»êÀÇ´ë, ¼¿ï¾Æ»êº´¿ø ½ÉÀå³»°ú |
|
Ä®½· ±æÇ×Á¦(Efonidipine)
2005³â Ãß°èÇмú´ëȸ
ÀÌÈ«¼ö, ÀÌ´ë¸ñµ¿º´¿ø °¡Á¤ÀÇÇаú |
|
°³¿øÀǰ¡ ¹Ýµå½Ã ¾Ë¾Æ¾ß ÇÒ ¹è´¢Àå¾Ö Áúȯ - °ú¹Î¼º¹æ±¤(OverActive Bladder, OAB)-
2005³â Ãß°èÇмú´ëȸ
±èÁØÃ¶, °¡Å縯ÀÇ´ë ºñ´¢±â°ú |
|
´ç´¢º´ Ä¡·áÀÇ ÃֽŠÁö°ß
2005³â Ãß°èÇмú´ëȸ
Á¤Àΰæ, ÇѸ²ÀÇ´ë ³»ºÐºñ³»°ú |
|
ÀÏÂ÷Áø·á¿¡¼ NSAIDS »ç¿ëÀÇ ÃֽŠÁö°ß
2005³â Ãß°èÇмú´ëȸ
À¯ºó, ¼¿ï¾Æ»êº´¿ø ·ù¸¶Æ¼½º³»°ú |
|
Drug-Nutrient Interactions
2005³â Ãß°èÇмú´ëȸ
¿©¿¡½º´õ, ¿¡½º´õ Ŭ¸®´Ð |
|
Protein Diet
2005³â Ãß°èÇмú´ëȸ
¹Ú¿ë¿ì, ¼º±Õ°üÀÇ´ë °ºÏ»ï¼ºº´¿ø ºñ¸¸Ã¼Çü°ü¸®Å¬¸®´Ð |
|